SVB Wealth’s Bicycle Therapeutics BCYC Stock Holding History

SVB Wealth’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-210	Closed	-$1.78K	–	625
2025 Q1	$1.78K	Buy	+210	New	+$2.47K	﹤0.01%	1258

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

SVB Wealth's BCYC Position: Q2 2025 in Review

SVB Wealth sold out of Bicycle Therapeutics (BCYC) in Q2 2025, closing a stake of 210 shares — an estimated $1.78K sold.

SVB Wealth first reported a position in BCYC in Q1 2025 and held it in 1 quarter. The position peaked at $1.78K in Q1 2025. 110 funds tracked by Wall St. Rank hold BCYC as of Q2 2025.

SVB Wealth reported no remaining Bicycle Therapeutics position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 210 Bicycle Therapeutics shares in Q2 2025, an estimated $1.78K.
SVB Wealth first reported a position in Bicycle Therapeutics in Q1 2025 and held it in 1 quarter.
SVB Wealth's Bicycle Therapeutics position peaked at $1.78K in Q1 2025.
110 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.